Thalassaemia alpha – Diagnostics – Overview of Information and Clinical Research

Alpha thalassaemia is an inherited blood disorder that affects how the body produces haemoglobin, the protein in red blood cells that carries oxygen throughout the body. Understanding when to seek testing and what diagnostic methods are available can help people recognise this condition early and receive appropriate care.

Introduction: Who Should Undergo Diagnostics

Diagnosing alpha thalassaemia is important for several groups of people, though not everyone needs testing. The condition is most common in people whose families come from parts of the world where malaria has been or remains widespread. This includes Southeast Asia, Mediterranean countries, Africa, the Middle East, India, and Central Asia. If your family has roots in these regions, you may want to consider getting tested, especially if you plan to have children.^[1]

Sometimes people discover they have alpha thalassaemia when they experience symptoms of anaemia, which means having too few red blood cells. Anaemia can cause tiredness, weakness, pale skin, shortness of breath, and dizziness. However, many people with mild forms of alpha thalassaemia have no symptoms at all and only learn about their condition through routine blood tests or during pregnancy screening.^[2]

Pregnant women may be offered screening for alpha thalassaemia, particularly if they belong to high-risk ethnic groups. This is especially important because if both parents carry certain gene changes, their baby could have a severe form of the condition. Early diagnosis during pregnancy allows families to understand the risks and make informed decisions about their care.^[13]

Parents who already have a child with alpha thalassaemia should also consider testing for themselves and other family members. Since this condition runs in families, knowing whether siblings or other relatives are carriers or affected can be valuable information for their future health planning.^[5]

⚠️ Important

If you are planning to have children and you or your partner have family history from high-risk regions, consider getting tested before pregnancy. This allows time for genetic counselling and helps you understand what to expect. Couples where both partners carry alpha thalassaemia genes face a higher risk of having a child with severe forms of the condition.

Diagnostic Methods for Alpha Thalassaemia

Diagnosing alpha thalassaemia involves several steps, starting with simple blood tests and progressing to more specialised examinations if needed. The diagnostic process aims to determine not only whether someone has alpha thalassaemia, but also which type and how severe it is. This information helps doctors provide the right care and advice.

Complete Blood Count

The first step in diagnosing alpha thalassaemia is usually a complete blood count, often abbreviated as CBC. This common blood test measures different components of your blood, including red blood cells, white blood cells, and platelets. In people with alpha thalassaemia, the CBC typically shows smaller than normal red blood cells and sometimes a reduced number of red blood cells overall.^[12]

A key measurement in the CBC is the mean corpuscular volume or MCV, which tells doctors how large the red blood cells are. When the MCV is reduced, meaning the cells are smaller than normal, and the person is not anaemic due to iron deficiency, doctors may suspect thalassaemia. However, this test alone cannot confirm alpha thalassaemia or distinguish it from other blood disorders, so additional testing is needed.^[13]

Blood Smear Examination

After the CBC, doctors often examine a blood smear under a microscope. This involves spreading a drop of blood thinly on a glass slide and staining it with special dyes. By looking at the blood cells directly, doctors can see their shape, size, and structure. In alpha thalassaemia, red blood cells may appear small and pale, and there may be variations in their size and shape.^[3]

In people with haemoglobin H disease, which is a moderate to severe form of alpha thalassaemia caused by three defective genes, the blood smear may show distinctive cells with a pattern that looks like golf balls under the microscope. These are red blood cells with abnormal haemoglobin H accumulated inside them. This finding can be a helpful clue in diagnosis.^[3]

Haemoglobin Electrophoresis

Haemoglobin electrophoresis is a laboratory test that separates different types of haemoglobin in the blood and measures how much of each type is present. Normal adult blood contains mostly haemoglobin A, with small amounts of haemoglobin A2 and very little fetal haemoglobin. In alpha thalassaemia, the pattern can be different depending on which type a person has.^[12]

This test is particularly useful for detecting abnormal forms of haemoglobin. In newborns with severe alpha thalassaemia major, doctors find high levels of haemoglobin Bart, an abnormal type that cannot carry oxygen effectively. In people with haemoglobin H disease, the test reveals the presence of haemoglobin H, another abnormal form. However, people who are silent carriers or have alpha thalassaemia trait may have normal or nearly normal results on this test, making diagnosis more challenging.^[12]

Iron Studies

Because alpha thalassaemia causes small red blood cells, it can be confused with iron deficiency anaemia, which also produces small red blood cells. To tell these conditions apart, doctors often check ferritin levels and other markers of iron in the body. In alpha thalassaemia, iron levels are typically normal or even high, whereas in iron deficiency they are low. This distinction is important because treating alpha thalassaemia with iron supplements is unnecessary and can actually be harmful.^[12]

DNA Testing and Genetic Analysis

The most definitive way to diagnose alpha thalassaemia is through DNA sequencing and genetic testing. Alpha thalassaemia is caused by changes in the genes called HBA1 and HBA2, which provide instructions for making alpha globin, a component of haemoglobin. Everyone has four copies of these alpha globin genes—two from each parent.^[1]

Genetic testing can identify whether genes are deleted or contain other mutations that prevent them from working properly. The number of affected genes determines the severity of the condition. One or two defective genes usually cause no symptoms or only mild anaemia. Three defective genes result in haemoglobin H disease with moderate to severe anaemia. Four defective genes lead to alpha thalassaemia major, the most severe form.^[3]

There are approximately 130 known mutations that can cause alpha thalassaemia. Most commonly, parts of the genes are deleted entirely, but sometimes the genes are present but contain changes that stop them from producing alpha globin effectively. DNA testing can identify exactly which type of mutation a person has, which helps predict how the condition will affect them and what risks they might pass to their children.^[3]

Prenatal and Newborn Screening

For couples at risk of having a baby with severe alpha thalassaemia, several prenatal diagnostic tests are available. Chorionic villus sampling involves taking a small sample of tissue from the placenta, usually between 10 and 13 weeks of pregnancy. Amniocentesis involves taking a sample of the fluid surrounding the baby, typically between 15 and 20 weeks of pregnancy. Both procedures allow doctors to analyse the baby’s DNA and determine whether the baby has inherited alpha thalassaemia and how severe it might be.^[12]

Fetal ultrasound examinations during pregnancy can detect signs of severe alpha thalassaemia major, such as hydrops fetalis, a condition where excess fluid builds up in the baby’s body. This occurs because severe anaemia causes the baby’s heart to work too hard, leading to heart failure and fluid accumulation. Ultrasound may show swelling in the baby’s body, an enlarged liver and spleen, and excess fluid around the baby. When these signs appear, additional testing can confirm the diagnosis.^[1]

After birth, newborn screening programs in some countries include tests for haemoglobin disorders. A small blood sample, usually taken from a heel prick, can be tested for abnormal haemoglobin types. Babies with alpha thalassaemia major have very high levels of haemoglobin Bart at birth. However, mild forms of alpha thalassaemia may not be detected by standard newborn screening.^[3]

Diagnostics for Clinical Trial Qualification

When patients with alpha thalassaemia are being considered for enrolment in clinical trials, they typically need to undergo comprehensive diagnostic testing to confirm their eligibility. Clinical trials are research studies that test new treatments or approaches to managing the condition, and they have specific requirements about which patients can participate.

The standard diagnostic tests required for clinical trial qualification usually include a complete blood count to document the degree of anaemia and the characteristics of the red blood cells. Haemoglobin levels are particularly important, as many trials specify minimum or maximum haemoglobin values for participants. For example, trials testing new treatments for haemoglobin H disease might require participants to have haemoglobin levels within a certain range to ensure the study can measure whether the treatment makes a difference.^[9]

Genetic confirmation through DNA testing is nearly always required for clinical trial participation. This ensures that participants truly have alpha thalassaemia and identifies exactly which genetic mutations they carry. Some trials may focus on specific types of mutations, so knowing the precise genetic changes is essential. The genetic analysis also helps researchers understand whether different mutations respond differently to the treatment being studied.^[3]

For trials involving transfusion-dependent patients, the medical team needs documentation of transfusion history. This includes records of how often transfusions have been needed, how much blood has been transfused, and whether there have been any complications. Trials may require participants to have a stable transfusion schedule for a certain period before joining the study.^[9]

Iron status testing is commonly required because iron overload is a major concern in people receiving regular blood transfusions. Tests may include serum ferritin levels, which indicate how much iron is stored in the body, and sometimes more detailed assessments like magnetic resonance imaging of the liver and heart to measure iron deposits in these organs. Trials testing iron removal treatments would particularly need this information.^[10]

⚠️ Important

Clinical trials may require additional specialised tests beyond standard diagnostic procedures. These might include heart function tests, liver function tests, tests for infections like hepatitis or HIV, and assessments of organ damage from iron overload. The specific requirements vary depending on what the trial is studying and what safety information researchers need to ensure participants can safely receive the experimental treatment.

For trials involving stem cell transplantation, which is being explored as a potential cure for severe alpha thalassaemia, extensive testing is required. This includes detailed genetic matching between the patient and potential donors, comprehensive organ function tests, and assessments of overall health to determine whether the patient can safely undergo the transplant procedure. These trials are typically offered only at specialised centres with expertise in both thalassaemia and transplantation.^[13]

Some newer clinical trials are testing gene therapy approaches for alpha thalassaemia. These cutting-edge studies may require even more detailed genetic and molecular testing to understand exactly how the patient’s cells are functioning and whether they are good candidates for genetic modification. Blood stem cells may be collected and analysed before the patient can be accepted into the trial.^[11]

Prognosis and Survival Rate

Prognosis

The outlook for people with alpha thalassaemia varies dramatically depending on which type they have. People who are silent carriers or have alpha thalassaemia trait typically have a normal life expectancy and experience little to no impact on their daily lives. They may have mild anaemia or no anaemia at all, and they generally do not need any medical treatment. These individuals can live completely normal lives, though it is important for them to know their carrier status for family planning purposes.^[2]

For people with haemoglobin H disease, which results from three defective alpha globin genes, the prognosis is generally good with appropriate medical care. Most individuals with this condition can live relatively normal lives, though they may experience moderate anaemia and need occasional blood transfusions, particularly during infections or other times of physical stress. With regular monitoring and treatment, people with haemoglobin H disease typically live into adulthood and can lead active, productive lives.^[4]

The prognosis has improved significantly over recent decades for people requiring regular transfusions. Access to safe blood supplies, better iron removal therapies, and comprehensive medical care have extended both the lifespan and quality of life for affected individuals. However, complications from iron overload remain a concern. Without proper treatment to remove excess iron, people can develop serious problems with their heart, liver, and hormone-producing glands. These complications can lead to early death, historically often by age 30 from cardiac complications, though modern chelation therapy has greatly improved outcomes.^[12]

For alpha thalassaemia major, historically the prognosis was very poor, with most affected babies dying before or shortly after birth due to severe anaemia and heart failure. However, advances in fetal medicine now offer hope. When diagnosed early during pregnancy, some babies can receive blood transfusions while still in the womb, and after birth they can continue with regular transfusions. Some may even be candidates for stem cell transplantation, which can potentially cure the condition. Still, alpha thalassaemia major remains the most serious form and requires intensive, lifelong medical care.^[13]

Several factors affect prognosis beyond the type of alpha thalassaemia. Access to regular medical care and adherence to treatment recommendations are crucial. People who consistently receive their scheduled transfusions and take their iron-removal medications as prescribed generally have better outcomes than those who do not. The development of complications such as infections, organ damage from iron overload, or immune reactions to transfusions can also affect long-term outlook.^[14]

Survival Rate

Specific survival statistics for alpha thalassaemia vary by type and access to medical care. People with alpha thalassaemia silent carrier status or alpha thalassaemia trait have the same life expectancy as the general population, as these forms cause no significant health problems.^[2]

For haemoglobin H disease, most affected individuals live well into adulthood with appropriate care. While specific survival percentages are not widely reported in the medical literature, the condition is generally considered compatible with a near-normal lifespan when properly managed. The key is regular medical follow-up and treatment of any complications that arise.^[4]

For people with severe forms requiring regular transfusions, survival has improved dramatically over the past several decades. Before modern chelation therapy to remove excess iron became available, many patients with transfusion-dependent thalassaemia died in their late teens or twenties from heart complications caused by iron overload. Now, with proper treatment including regular transfusions and effective iron removal therapy, many patients are living into their 40s, 50s, and beyond.^[12]

Alpha thalassaemia major has historically had extremely poor survival, with most affected babies dying before birth or in the newborn period. However, with emerging treatments including in-utero transfusions and the possibility of stem cell transplantation after birth, some babies are now surviving. Long-term survival data for these newer approaches is still being gathered as these treatments are relatively recent developments.^[13]

It is important to understand that survival statistics represent averages and may not predict any individual person’s outcome. Many factors influence survival, including the specific genetic mutations involved, the quality and consistency of medical care, how well a person adheres to their treatment plan, whether complications develop, and overall health status. Advances in treatment continue to improve outcomes, meaning that statistics from even a few years ago may not reflect current survival rates.^[14]

#1 Clinical Trials Search in Europe